Last reviewed · How we verify
Anagrelide CR
Anagrelide CR works by inhibiting platelet aggregation and reducing platelet count.
Anagrelide CR works by inhibiting platelet aggregation and reducing platelet count. Used for Essential thrombocythemia.
At a glance
| Generic name | Anagrelide CR |
|---|---|
| Also known as | GALE-401 |
| Sponsor | Galena Biopharma, Inc. |
| Drug class | platelet aggregation inhibitor |
| Target | cAMP |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
Anagrelide CR is a platelet aggregation inhibitor that acts by blocking the action of cyclic adenosine monophosphate (cAMP) on platelets, leading to a decrease in platelet count. This mechanism is thought to be responsible for its therapeutic effects in reducing the risk of thrombotic events.
Approved indications
- Essential thrombocythemia
Common side effects
- Headache
- Nausea
- Dizziness
- Fatigue
- Palpitations
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anagrelide CR CI brief — competitive landscape report
- Anagrelide CR updates RSS · CI watch RSS
- Galena Biopharma, Inc. portfolio CI